Central Nervous System Pathology

Inclusion Criteria

- Participant must be at least 18 years of age at the time of signing the informed consent. 
- Known or highly suspected CNS pathology (contrast-enhancing CNS lesion) referred for contrast-enhanced MRI of the CNS. 
- Male and female. 
- Estimated glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m^2.

Exclusion Criteria

- Considered clinically unstable or has a concomitant/intercurrent condition (e.g. COVID-19 infection) that would not allow participation for the full planned study period (i.e. period 1, 2 or both) in the judgement of the investigator. 
- Severe cardiovascular disease. 
- Patients undergoing liver transplantation.
- Any contraindication to MRI examinations. 
- History of severe allergic or anaphylactic/anaphylactoid reaction to any allergen including drugs and contrast agents, foods, chemicals or other substances. 
- History of allergic asthma and/ or atopic dermatitis. 
- Suspected lesions or suffering from any of the following CNS diseases/lesion types as the main indication for MRI: 
-- Lepto-meningeal disease (e.g. leptomeningeal carcinomatosis). Dural lesions (e.g. meningiomas) fulfilling inclusion criteria #2 are not excluded
-- Pituitary adenomas (macro and micro) 
-- Tumors of the choroid plexus 
-- Tumors of the pineal gland 
-- Dermoid/epidermoid tumors 
-- Infectious disease (e.g. brain abscess, cisticercosis, etc.) 
-- Venous angiomas 
-- Subacute/chronic ischemia 
-- Encephalitis 
-- Multiple sclerosis (acute and chronic) 
-- Optic neuritis 
-- Chordomas 
-- Von Hippel Lindau syndrome 
-- Hypertensive leukoencephalopathy. 
- Receipt of any contrast agent < 72 h prior to the study MRIs, or planned receipt of any contrast agent within 72 h after the second study MRI. 
- Planned or expected biopsy in the region of interest or any interventional therapeutic procedure from the first study MRI up to 24 h after the second study MRI. 
- Planned or expected change in any treatment or procedure between the two study MRIs that may alter image comparability and /or chemotherapy which is changed between the two MRI procedures. 
- Contraindications to the administration of gadobutrol, as specified in the local product label.